Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC/QTOF/MS platform

Acta Oncologica

Volumn 51, Issue 4, 2012, Pages 473-479

  Fan, Lijun ^a   Zhang, Wang ^a   Yin, Mingzhu ^a   Zhang, Tao ^a   Wu, Xiaoyan ^a   Zhang, Haiyu ^a   Sun, Meng ^a   Li, Zhenzi ^a   Hou, Yan ^a   Zhou, Xiaohua ^b   Lou, Ge ^a   Li, Kang ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CERAMIDE; DEMETHYLPHYTOMENADIONE; GANGLIOSIDE; LYSOPHOSPHOLIPID; N' FORMYLKYNURENINE; PHYTOSPHINGOSINE; TUMOR MARKER; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL OVARIAN CANCER; FEMALE; HUMAN; METABOLOMICS; OVARY CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TIME OF FLIGHT MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY QUADRUPOLE TIME OF FLIGHT MASS SPECTROMETRY; UPREGULATION; VALIDATION STUDY;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AREA UNDER CURVE; CASE-CONTROL STUDIES; CHROMATOGRAPHY, LIQUID; CYSTADENOCARCINOMA, SEROUS; DISCRIMINANT ANALYSIS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; LEAST-SQUARES ANALYSIS; METABOLOMICS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; ROC CURVE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84859783281     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2011.648338     Document Type: Article

References (27)

1. Teneriello MG, Park RC. Early detection of ovarian cancer. CA Cancer J Clin 1995;45:71-87.
2. American Cancer Society. Cancer facts & fi gures 2010. Atlanta: American Cancer Society; 2010.
3. Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004;3:355-66.
4. Williams TI, Toups KL, Saggese DA, Kalli KR, Cliby WA, Muddiman DC. Epithelial ovarian cancer: Disease etiology, treatment, detection, and investigational gene, metabolite, and protein biomarkers. J Proteome Res 2007;6:2936-62.
5. Li M, Wang B, Zhang M, Rantalainen M, Wang S, Zhou H, et al. Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci USA 2008;105:2117-22.
6. Cao H, Huang H, Xu W, Chen D, Yu J, Li J, et al. Fecal metabolome pro fi ling of liver cirrhosis and hepatocellular carcinoma patients by ultra performance liquid chromatography-mass spectrometry. Anal Chim Acta 2011;691:68-75.
7. Gold J. Metabolic profi les in human solid tumors. I. A new technic for the utilization of human solid tumors in cancer research and its application to the anerobic glycolysis of isologous benign and malignant colon tissues. Cancer Res 1966;26:695-705.
8. Griffi n JL, Shockcor JP. Metabolic profi les of cancer cells. Nat Rev Cancer 2004;4:551-61.
9. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profi les delineate potential role for sarcosine in prostate cancer progression. Nature 2009;457:910-4.
10. Gowda GA, Zhang S, Gu H, Asiago V, Shanaiah N, Raftery D. Metabolomics-based methods for early disease diagnostics. Expert Rev Mol Diagn 2008;8:617-33.
11. Bartella L, Thakur SB, Morris EA, Dershaw DD, Huang W, Chough E, et al. Enhancing nonmass lesions in the breast: Evaluation with proton (1H) MR spectroscopy. Radiology 2007;245:80-7.
12. Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications of metabolomics in oncology: A review. Clin Cancer Res 2009;15:431-40.
13. Odunsi K, Wollman RM, Ambrosone CB, Hutson A, McCann SE, Tammela J, et al. Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics. Int J Cancer 2005; 113:782-8.
14. Garcia E, Andrews C, Hua J, Kim HL, Sukumaran DK, Szyperski T, et al. Diagnosis of early stage ovarian cancer by 1H NMR metabonomics of serum explored by use of a microfl ow NMR probe. J Proteome Res 2011;10:1765-71.
15. Chen J, Zhang X, Cao R, Lu X, Zhao S, Fekete A, et al. Serum 27-nor-5beta-cholestane-3,7,12,24,25 pentol glucuronide discovered by metabolomics as potential diagnostic biomarker for epithelium ovarian cancer. J Proteome Res 2011;10:2625-32.
16. Breiman L. Random forests. Machine Learning 2001;45:5- 3 2.
17. Diaz-Uriarte R, de Andres SA. Gene selection and classifi cation of microarray data using random forest. BMC Bioinformatics 2006;7:3.
18. Tcherkassova J, Abramovich C, Moro R, Chen C, Schmit R, Gerber A, et al. Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer. Tumour Biol 2011;32:831-8.
19. Hannun YA, Luberto C, Argraves KM. Enzymes of sphingolipid metabolism: From modular to integrative signaling. Biochemistry 2001;40:4893-903.
20. Saad AF, Meacham WD, Bai A, Anelli V, Elojeimy S, Mahdy AE, et al. The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy. Cancer Biol Ther 2007;6:1455-60.
21. Dziecedil GP, Owczarek T, Plazuk E, Gomulkiewicz A, Majchrzak M, Podhorska-Okolow M, et al. Ceramide galactosyltransferase (UGT8) is a molecular marker of breast cancer malignancy and lung metastases. Br J Cancer 2010;103:524-31.
22. Sutphen R, Xu Y, Wilbanks GD, Fiorica J, Grendys EC Jr, LaPolla JP, et al. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2004;13:1185-91.
23. Monet M, Gkika D, Lehen'kyi V, Pourtier A, Vanden Abeele F, Bidaux G, et al. Lysophospholipids stimulate prostate cancer cell migration via TRPV2 channel activation. Biochim Biophys Acta 2009;1793:528-39.
24. Sengupta S, Kim KS, Berk MP, Oates R, Escobar P, Belinson J, et al. Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion. Oncogene 2007;26:2894-901.
25. Springett GM, Bonham L, Hummer A, Linkov I, Misra D, Ma C, et al. Lysophosphatidic acid acyltransferase-beta is a prognostic marker and therapeutic target in gynecologic malignancies. Cancer Res 2005;65:9415-25.
26. Mocchetti I. Exogenous gangliosides, neuronal plasticity and repair, and the neurotrophins. Cell Mol Life Sci 2005;62: 2283-94.
27. Birkle S, Zeng G, Gao L, Yu RK, Aubry J. Role of tumorassociated gangliosides in cancer progression. Biochimie 2003;85:455-63.